Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study

References

• Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: a Review. JAMA. 2021;326(9):851–862. doi:10.1001/jama.2021.13027
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Wong MCS, Jiang JY, Liang M, Fang Y, Yeung MS, Sung JJY. Global temporal patterns of pancreatic cancer and association with socioeconomic development. Sci Rep. 2017;7(1):3165. doi:10.1038/s41598-017-02997-2
   PubMedGoogle Scholar
• Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23(7):1880–1888. doi:10.1093/annonc/mdr541
   PubMed Web of Science ®Google Scholar
• Jiao L, Berrington de Gonzalez A, Hartge P, et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control. 2010;21(8):1305–1314. doi:10.1007/s10552-010-9558-x
   PubMed Web of Science ®Google Scholar
• Rahn S, Zimmermann V, Viol F, et al. Diabetes as risk factor for pancreatic cancer: hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells. Cancer Lett. 2018;415:129–150. doi:10.1016/j.canlet.2017.12.004
   PubMed Web of Science ®Google Scholar
• Lucenteforte E, La Vecchia C, Silverman D, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012;23(2):374–382. doi:10.1093/annonc/mdr120
   PubMed Web of Science ®Google Scholar
• Gandhi S, de la Fuente J, Murad MH, Majumder S. Chronic Pancreatitis Is a Risk Factor for Pancreatic Cancer, and Incidence Increases With Duration of Disease: a Systematic Review and Meta-analysis. Clin Transl Gastroenterol. 2022;13(3):e00463. doi:10.14309/ctg.0000000000000463
   PubMed Web of Science ®Google Scholar
• Matsuki R, Okano N, Hasui N, et al. Trends in the surgical treatment for pancreatic cancer in the last 30 years. Biosci Trends. 2022;16(3):198–206. doi:10.5582/bst.2022.01250
   PubMed Web of Science ®Google Scholar
• Speer AG, Thursfield VJ, Torn-Broers Y, Jefford M. Pancreatic cancer: surgical management and outcomes after 6 years of follow-up. Med J Aust. 2012;196(8):511–515. doi:10.5694/mja11.10890
   PubMed Web of Science ®Google Scholar
• Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–2020. doi:10.1016/s0140-6736(20)30974-0
   PubMed Web of Science ®Google Scholar
• Tempero MA. NCCN Guidelines Updates: pancreatic Cancer. J Natl Compr Canc Netw. 2019;17(5.5):603–605. doi:10.6004/jnccn.2019.5007
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439–457. doi:10.6004/jnccn.2021.0017
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395–2406. doi:10.1056/NEJMoa1809775
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Okusaka T, Ikeda M, Fukutomi A, et al. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105(10):1321–1326. doi:10.1111/cas.12501
   PubMed Web of Science ®Google Scholar
• van Roessel S, van Veldhuisen E, Klompmaker S, et al. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncol. 2020;6(11):1733–1740. doi:10.1001/jamaoncol.2020.3537
   PubMed Web of Science ®Google Scholar
• Mukherji R, Debnath D, Hartley ML, Noel MS. The Role of Immunotherapy in Pancreatic Cancer. Curr Oncol. 2022;29(10):6864–6892. doi:10.3390/curroncol29100541
   PubMed Web of Science ®Google Scholar
• Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 2014;153(1):145–152. doi:10.1016/j.clim.2014.04.010
   PubMed Web of Science ®Google Scholar
• Chick RC, Gunderson AJ, Rahman S, Cloyd JM. Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: challenges and Early Results. Cancers. 2023;15(15):56.
   Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(8):1028–1061. doi:10.6004/jnccn.2017.0131
   PubMed Web of Science ®Google Scholar
• Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051–1059. doi:10.1001/jamaoncol.2015.2639
   PubMed Web of Science ®Google Scholar
• Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Cancer. Int J Mol Sci. 2019;20(18). doi:10.3390/ijms20184504
   Web of Science ®Google Scholar
• Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic Cancer: pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology. 2022;163(2):386–402.e1. doi:10.1053/j.gastro.2022.03.056
   PubMed Web of Science ®Google Scholar
• De Dosso S, Siebenhüner AR, Winder T, et al. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96:102180. doi:10.1016/j.ctrv.2021.102180
   PubMed Web of Science ®Google Scholar
• Li S, Xu HX, Wu CT, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019;22(1):15–36. doi:10.1007/s10456-018-9645-2
   PubMed Web of Science ®Google Scholar
• National Health Commission Of The People’s Republic Of C. Chinese guidelines for diagnosis and treatment of pancreatic cancer 2018 (English version). Chin J Cancer Res. 2019;31(2):278–294. doi:10.21147/j.issn.1000-9604.2019.02.03
   PubMed Web of Science ®Google Scholar
• Ravindranathan S, Passang T, Li JM, et al. Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Nat Commun. 2022;13(1):6418. doi:10.1038/s41467-022-34242-4
   PubMed Web of Science ®Google Scholar
• Blair AB, Wang J, Davelaar J, et al. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Gastroenterology. 2022;163(5):1267–1280.e7. doi:10.1053/j.gastro.2022.06.027
   PubMed Web of Science ®Google Scholar
• Falcomatà C, Bärthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D. Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Cancer Discov. 2023;13(2):278–297. doi:10.1158/2159-8290.Cd-22-0876
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E, Andreou A, Wenning AS, Gloor B, Perren A. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Eur J Cancer. 2022;169:64–73. doi:10.1016/j.ejca.2022.03.033
   PubMed Web of Science ®Google Scholar
• Lawlor RT, Mattiolo P, Mafficini A, et al. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: systematic Review and Still-Open Questions. Cancers. 2021;13(13):68.
   Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015;21(19):4286–4293. doi:10.1158/1078-0432.Ccr-14-2607
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Blaydorn L, Beck J, et al. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018;36(1):96–102. doi:10.1007/s10637-017-0525-1
   PubMed Web of Science ®Google Scholar
• Song D, Yang X, Guo X, Sun H. Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer. Immunotherapy. 2022;14(16):1307–1313. doi:10.2217/imt-2022-0196
   PubMed Web of Science ®Google Scholar
• Zhou L, Wu Z, Jiang C, Efficacy DS. Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer. Comput Math Methods Med. 2022;2022:5430720. doi:10.1155/2022/5430720
   PubMed Web of Science ®Google Scholar
• Del Re M, Vivaldi C, Rofi E, et al. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Cancers. 2021;13(15):76.
   Web of Science ®Google Scholar
• Sriram G, Milling LE, Chen JK, et al. The injury response to DNA damage in live tumor cells promotes antitumor immunity. Sci Signal. 2021;14(705):eabc4764. doi:10.1126/scisignal.abc4764
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–741. doi:10.1038/s41571-020-0413-z
   PubMed Web of Science ®Google Scholar
• Gao Z, Bai Y, Lin A, et al. Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. Mol Cancer. 2023;22(1):31. doi:10.1186/s12943-023-01722-0
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang Y, Yang F, Zhang Y, Jiang M, Zhang X. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: a Retrospective Monocentric Study. Cancer Manag Res. 2022;14:535–546. doi:10.2147/cmar.S349442
   PubMed Web of Science ®Google Scholar
• Usón PLSJ, Tolentino FDS, Santos VM, Rother ET, Maluf FC. The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies. PLoS One. 2020;15(3):e0230060. doi:10.1371/journal.pone.0230060
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi:10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar